SSM4 (4th Summer School on Medicines)
2 July 2-13, 2012 – Montréal (Québec) CANADA
www.ssm4.org
SSM4, the Fourth Summer School on Medicines offers a unique 70--hour training
program under a multicultural sponsorship in the wonderful setting of Montreal,
Quebec. Make plans now for two full weeks of lively presentations and direct
interactions with the Faculty, including two Case Studies and Workshops with Industry,
covering the whole value chain of medicines, from “idea to market”. The Faculty
members are leaders in their field and contribute to create one of the most innovative
and focused programs in drug discovery and development currently offered.
Scientific committee
Denis deBlois, U de Montréal (www.umontreal.ca)
Brian White-Guay, U de Montréal (www.umontreal.ca)
Michelle Savoie, U de Montréal et Montreal-InVivo (www.montreal-invivo.com)
Roland Bugat, Institut Claudius Regaud (http://eng.claudiusregaud.fr/)
Christophe Cazaux, U de Toulouse III, Oncopole (www.oncopole-toulouse.com)
Pierre Cordelier U de Toulouse III, Oncopole (www.oncopole-toulouse.com)
Jordi Quintana, Parc Cientific de Barcelona (www.pcb.ub.edu)
Marta Princep, Biocat (www.biocat.ca)
Organizing committee:
Francis Beaulieu, Montreal-InVivo (www.montreal-invivo.com)
Brian White-Guay (U de Montréal (www.umontreal.ca)
Lionel Havion, Fondation InNaBio Santé (www.innabiosante.fr)
Jean-Louis Molina, , Institut Claudius Regaud (http://eng.claudiusregaud.fr/)
Nerea Alonso, Biocat (www.biocat.ca)
MONDAY, July 2nd
08:30 – 09:00
Registration
OFFICIAL OPENING – 4th Summer School on Medicines (SSM4)
09:00 – 09:15
Denis deBlois, Chairman, SSM4 Scientific Committee
Pierre Moreau, Dean, Faculty of Pharmacy Université de Montréal
Michelle Savoie, Director, Montréal in Vivo
Pierre Cordelier, Université Paul-Sabatier/ Oncopole, Toulouse
SESSION 1 : NEW MEDICINES: AN OVERVIEW FROM IDEA TO MARKET
Chairperson: Denis deBlois, Université de Montreal
09:15 – 10:15
Drug discovery
Denis de Blois, Université de Montréal, Québec
10:15 – 10:45
Health Break
10:45 – 11:45
Translational medicine
Denis de Blois, Université de Montréal, Québec
Brian White-Guay, Université de Montreal, Québec
11:45 – 13:15
Lunch
13:15 – 14:30
Clinical development
Brian White-Guay, Université de Montreal, Québec
14:30 – 15:30
Molecules and Money
Jeffery Elliott, Sectoral Asset Management, Montreal
15:30 – 16:00
Health Break
16:00 – 17:00
Evolving models of pharma R&D: Introductory remarks & panel
Philippe Walker, V-P Astra Zeneca R&D
17:00 – 19:00
Welcome Reception in Montreal
TUESDAY, July 3rd
SESSION 2 : DRUG DISCOVERY
Chairperson: Denis de Blois, Université de Montreal
08:30 – 9:15
Target identification and validation
Marc Servant, Université de Montreal
9:15 – 10:00
Assessing target function
Michael A Adams, Queen’s University, Kingston, ON
10:00 – 10:30
Health break
10:30 – 11:15
The medicinal chemistry of small molecules
Eric Marsault, Université de Sherbrooke
11:15 – 12:00
Case example: Preclinical development of a molecule with an
original mechanism of action against leukemia
Christian Recher, Toulouse
12:00 – 13:30
Lunch
13:30 – 14:15
Biologicals: discovery and development
Jean-François Gauchat, Université de Montréal
14:15 – 15:00
Targeting shifting targets: constraints in the area of antibacterials
Karine Auclair, McGill University
15:00 – 15:30
Health break
15:30 – 16:15
Gene therapy: from preclinical to phase I
clinical trials
Pierre Cordelier, Toulouse
16:15 – 17:00
Panel Discussion
WEDNESDAY, July 4th
SESSION 3: NONCLINICAL DEVELOPMENT
Session Chairperson: Brian White-Guay, Université de Montreal
8:30 – 9:15
The absorption, distribution, metabolism and excretion of drugs
Véronique Michaud, Université de Montréal
9:15 – 10:00
Current Trends in Non-Clinical Safety Testing
Simon Authier, CiToxLAB
10:00 – 10:30
Health break
10.30 – 11:15
Unexpected & Unusual Adventures in Chemistry, Manufacturing &
Controls
Patrick Colin, Chief Development Officer, GiCare Pharma
11:15 – 12:00
Panel Discussion
12:00 – 13:30
Lunch
SESSION 4: CASE STUDY IN DRUG DISCOVERY AND DEVELOPMENT (I)
Development of GIC-1101: A novel analgesic with dual mechanisms of action
Case Study presented by: Patrick Colin, Chief Development Officer, GiCare Pharma
13:30 – 14:00
Case presentation and outline of challenges
14:00 – 15:00
Group session: Students work in small teams to tackle the challenges
15:00 – 15:30
Health break
15:30 – 17:00
Each team reports / General discussion
THURSDAY, July 5th
SESSION 5 : CLINICAL DEVELOPMENT
Chairperson: Brian White-Guay, Université de Montreal
08:30 – 9:15
ADME in humans : Issues and challenges
Jacques Turgeon, Université de Montreal
9:15 – 10:00
Learning trials : exposure – response and dose selection
Richard Lalonde, Pfizer, USA
10:00 – 10:30
Health break
10:30 – 11:15
Biomarkers in drug development
Patrice Hugo, Senior Global Director, LabCorp Clinical Trials
11:15 – 12:00
Panel Discussion
12:00 – 13:30
Lunch
13:30 – 14:15
Regulatory strategy and interactions: early development
Patrick Colin, GiCare Pharma, Canada
14:15 – 15:00
Regulatory strategy and interactions : late development
Brian White-Guay, Université de Montréal
15:00 – 15:30
Health break
15:30 – 16:15
From discovery to life cycle management: an integrated view of
drug development
Robin Godlstein, consultant, Boston
16:15 – 17:00
Panel Discussion
FRIDAY, July 6th
SESSION 6: CLINICAL TRIALS
Session Chairperson: Denis Querleu, Université Paul-Sabatier, McGill University
8:30 – 9:15
Late development design, analysis & interpretation of clinical trials
Raymond Bain, Merck USA
9:15 – 10:00
Late clinical development issues and challenges
Ted Reiss, Vanderbilt University, Nashville, USA
10:00 – 10:30
Health break
10.30 – 11:15
Value vigilance: What should we be looking for ?
Pierre Anhoury, Accenture, Toulouse
11:15 – 12:00
Panel Discussion
12:00 – 13:30
Lunch
SESSION 7: CASE STUDY IN DRUG DISCOVERY AND DEVELOPMENT (II)
Discovery of Montelukast: Endpoint / comparator selection; target product profile
Case Study presented by: Ted Reiss, Vanderbilt University, Nashville, USA
13:30 – 14:00
Case presentation and outline of challenges
14:00 – 15:00
Group session: Students work in small teams to tackle the challenges
15:00 – 15:30
Health break
15:30 – 16:15
Each team reports
16:15 – 17:00
How it really happened
SUNDAY, July 8th
9:00
Bus departure for Quebec City
12:00 –
Free Visit (PM)
19:00 –
Dinner in Old Quebec
MONDAY, July 9th
SESSION 8: MOLECULAR BIOMARKERS AND DEVELOPMENT OF POINT OF CARE
DIAGNOSTICS FOR INFECTIOUS DISEASES
Session Chairperson: Michel G Bergeron, Université Laval
9:00 – 12:00
A medical practice revolution : molecular diagnosis of infectious
diseases
Michel G Bergeron, Director and Founder, Centre de Recherche en
Infectiologie
12:00 – 13:30
Lunch
SESSION 9: INNOVATIVE VACCINE DEVELOPMENT PLATFORM
Session Chairperson: TBA
13:30 – 17:00
Medicago Research Center
Louis-Philippe Vézina, Medicago Inc.
17:00 –
Departure for Montreal (bus)
TUESDAY, July 10th
SESSION 10 : PHARMACOGIVILANCE AND RISK MANAGEMENT
Chairperson: Sylvie Perrault, Université de Montréal
08:30 – 9:15
Benefit-risk assessment in clinical decision making
James Brophy, McGill University
9:15 – 10:00
Pharmacovigilance and risk management considerations in Canada
Ariel E. Arias, Ctr for Blood and Tissues Evaluation, Health Canada
10:00 – 10:30
Health break
10:30 – 11:15
Global implementation of pharmacovigilance plans
Gervais Tougas, Novartis , Bâle
11:15 – 12:00
Panel Discussion
12:00 – 13:30
Lunch
SESSION 11 : MARKET ACCESS AND HEALTH TECHNOLOGY ASSESSMENT (HTA)
Chairperson: Jean Lachaine, Université de Montreal
13:30 – 14:15
The path towards reimbursement of pharmaceutical innovations in
Canada
Frédéric Lavoie, Pfizer
14:15 – 15:00
Market Access – Third Payer Perspective
Reiner Banken, INESS
15:00 – 15:30
Health break
15:30 – 16:15
HTA methodologies
Jean-Eric Tarride, McMaster University
16:15 – 17:00
Panel Discussion
WEDNESDAY, July 11th
SESSION 12: FINANCING THE VALUE CHAIN
Chairperson: (TBA)
08:30 – 9:15
From innovation to value
Anne-Marie Larose, Hema-Quebec
9:15 – 10:00
New trends in financing opportunities, models for start-ups
Elizabeth Douville, Amorchem
10:00 – 10:30
Health break
10:30 – 11:15
Global financing and partnerships
Elizabeth Stoner, MPM Capital, New-York
11:15 – 12:00
Panel Discussion
12:00 – 13:30
Lunch
SESSION 13: BUSINESS DEVELOPMENT
Chairperson: (TBA)
13:30 – 14:15
Stakeholders
Michelle Savoie, Université de Montréal,
14:15 – 15:00
Pharma vs. Biotech
Luc Vachon,
15:30 – 16:15
Panel Discussion
16:15 – 17:00
Poster session
THURSDAY, July 12th
SYMPOSIUM : Facing the current innovation challenge
Chairperson: Jean-Pierre Moreau, CytoxLab, Montreal
09:00 – 12:00
Networking Session
Speakers: TBA
Keynote speaker:
Times of Change in Drug Discovery and Chemical Biology: Hard
Lessons from the Last Decades
Dr. Chris Lipinski Scientific Advisor Melior Discovery Waterford, CT
12:00 – 13:30
Lunch
13:30 – 17:00
Scientific Session
Speakers: TBA
Keynote speaker:
Discovery of Telaprevir: A novel protease inhibitor for the treatment
of Hepatitis C virus infection
Ann Kwong, Vertex,
Poster session for SSM4 participants
17:00 – 19:00
Cocktail
FRIDAY, July 13th
SESSION 14:
NEW STRATEGIES
Session Chairperson: Jordi Quintana, Parc Científic de Barcelona
8:30 – 9:15
Genomics: present and future impact
Ivo Gut, Director, Natl Ctr for Genomic Analysis, Barcelona
9:15 – 10:00
Public –Private partnerships (PCB-Chembiobank)
Jordi Quintana, Parc Científic de Barcelona
10:00 – 10:30
Health break
10.30 – 11:15
Pre-competitive research / Open Innovation
Max Fehlmann, CQDM
11:15 – 12:00
Panel Discussion
12:00 – 13:30
Lunch
SESSION 15: CAREER PLANNING
Chairperson: Michelle Savoie, Université de Montréal et Montréal InVivo
13:30 – 14:15
Career profiles in life sciences. What are the opportunities?
Patrick Colin, Chief Development Officer, GiCare Pharma
14:15 – 15:00
Career development: what does it take?
Luc Vachon
15:00 – 16:00
Panel Discussion
16:00 – 16:15
SSM4 Closing comments and overture towards SSM5
Denis deBlois